1. <menuitem id="nbjb9"><p id="nbjb9"></p></menuitem>
      <nav id="nbjb9"><strike id="nbjb9"><bdo id="nbjb9"></bdo></strike></nav>
      1. <s id="nbjb9"><b id="nbjb9"><noscript id="nbjb9"></noscript></b></s>
        

      2. <rt id="nbjb9"><cite id="nbjb9"><samp id="nbjb9"></samp></cite></rt>

        <rt id="nbjb9"><option id="nbjb9"></option></rt>

        CN  /  EN

        imgboxbg

        NEWS

        最新消息

        Facebook wins the patent infringement lawsuit against Voxer in the UK

        • 分类:最新消息
        • 作者:华讯知识产权
        • 来源:
        • 发布时间:2021-11-17 15:08
        • 访问量:

        【概要描述】Facebook wins the patent infringement lawsuit against Voxer in the UK In May, the UK High Court found that social media platforms Facebook and Instagram do not infringe a patent owned by Voxer. Furthermore, Facebook succeeded in invalidating Voxer’s “Live Broadcast” patent. ? Voxer is an American app development company, and it is best known for its free Voxer Walkie Talkie app for smartphones, providing a live “push-to-talk” system and a voice messaging system. The patent in issue was EP (UK) 2 393 259 entitled “Telecommunication and Multimedia Management Method and Apparatus”. The invention relates to enabling two-mode conversation. Users can communicate in either a near-synchronous or “live” conversation. The two modes provide a user experience in a standard full-duplex phone call or in a series of back and forth time-delayed transmissions. Therefore, two individual users can send recorded voice messages back and forth to each other and review the messages whenever convenient, or at a rate where they essentially merge into a live, synchronous voice conversation. ? In 2020 in the UK, Voxer contended that Facebook infringed the EP259 patent through Facebook and Instagram’s live functionality feature over the iOS operating system. However, Facebook then counterclaimed the invalidity in 2021 as an action for revocation and denying infringement. Facebook challenged the validity on various grounds. Facebook mentioned two reference documents and stated that the claims lack novelty and/or are obvious over the prior art: WO 2006/121550 (Atarius) and US 2006/0003740 A1 (Munje). Both were published before the earlier claimed priority date of the patent. Facebook also stated that the claims are invalid for insufficiency. The patent was based on a lack of novelty and/or obviousness over two pieces of prior art cited by Voxer in its patent application. ? At first, presiding judge Birss allowed Voxer’s two unconditional claims to amend the patent, which made the patent novel, not obvious, and sufficient. Finally, however, Birss found the patent obvious over US 2006/0003740 A1 (Munje). As a result, the UK High Court has decided that EP 259 is non-infringed and invalid, and revoked the patent. The case therefore represents a success for Facebook in the UK, although proceedings are ongoing in the US and Germany. ? In the US and Germany, decisions have gone the other way for Facebook. In May 2021, the Patent Trial and Appeal Board in the Western District of Texas found four Voxer patents valid. Furthermore, in June, Munich Higher Regional Court found that the ‘Live’ functionality in the Facebook and Instagram iOS apps and the Facebook website infringed the Voxer patent. ? Coming from different decisions in three countries, the patent battle between the two companies is still hanging in the balance. Reference: Facebook and Voxer take live broadcast patent dispute to Europe - JUVE Patent (juve-patent.com) Facebook Ireland Ltd v Voxer IP LLC [2021] EWHC 657 (Pat) (19 March 2021) (bailii.org) Facebook Ireland Ltd v Voxer IP LLC [2020] EWHC 1806 (Pat) (07 July 2020) (bailii.org) https://www.bailii.org/ew/cases/EWHC/Patents/2021/1377.html https://www.theregister.com/2021/04/16/facebook_voxer_ip_patent_trial/ https://www.mondaq.com/uk/patent/1076680/facebook-ireland-limited-v-voxer-ip-llp https://jakemp.com/en/news/facebook-succeed-in-invalidating-voxers-live-broadcast-patent-in-the-uk

        Facebook wins the patent infringement lawsuit against Voxer in the UK

        【概要描述】Facebook wins the patent infringement lawsuit against Voxer in the UK

        In May, the UK High Court found that social media platforms Facebook and Instagram do not infringe a patent owned by Voxer. Furthermore, Facebook succeeded in invalidating Voxer’s “Live Broadcast” patent.

        ?

        Voxer is an American app development company, and it is best known for its free Voxer Walkie Talkie app for smartphones, providing a live “push-to-talk” system and a voice messaging system. The patent in issue was EP (UK) 2 393 259 entitled “Telecommunication and Multimedia Management Method and Apparatus”. The invention relates to enabling two-mode conversation. Users can communicate in either a near-synchronous or “live” conversation. The two modes provide a user experience in a standard full-duplex phone call or in a series of back and forth time-delayed transmissions. Therefore, two individual users can send recorded voice messages back and forth to each other and review the messages whenever convenient, or at a rate where they essentially merge into a live, synchronous voice conversation.

        ?

        In 2020 in the UK, Voxer contended that Facebook infringed the EP259 patent through Facebook and Instagram’s live functionality feature over the iOS operating system. However, Facebook then counterclaimed the invalidity in 2021 as an action for revocation and denying infringement. Facebook challenged the validity on various grounds. Facebook mentioned two reference documents and stated that the claims lack novelty and/or are obvious over the prior art: WO 2006/121550 (Atarius) and US 2006/0003740 A1 (Munje). Both were published before the earlier claimed priority date of the patent. Facebook also stated that the claims are invalid for insufficiency. The patent was based on a lack of novelty and/or obviousness over two pieces of prior art cited by Voxer in its patent application.

        ?

        At first, presiding judge Birss allowed Voxer’s two unconditional claims to amend the patent, which made the patent novel, not obvious, and sufficient. Finally, however, Birss found the patent obvious over US 2006/0003740 A1 (Munje). As a result, the UK High Court has decided that EP 259 is non-infringed and invalid, and revoked the patent. The case therefore represents a success for Facebook in the UK, although proceedings are ongoing in the US and Germany.

        ?

        In the US and Germany, decisions have gone the other way for Facebook. In May 2021, the Patent Trial and Appeal Board in the Western District of Texas found four Voxer patents valid. Furthermore, in June, Munich Higher Regional Court found that the ‘Live’ functionality in the Facebook and Instagram iOS apps and the Facebook website infringed the Voxer patent.

        ?

        Coming from different decisions in three countries, the patent battle between the two companies is still hanging in the balance.

        Reference:


        Facebook and Voxer take live broadcast patent dispute to Europe - JUVE Patent (juve-patent.com)
        Facebook Ireland Ltd v Voxer IP LLC [2021] EWHC 657 (Pat) (19 March 2021) (bailii.org)
        Facebook Ireland Ltd v Voxer IP LLC [2020] EWHC 1806 (Pat) (07 July 2020) (bailii.org)
        https://www.bailii.org/ew/cases/EWHC/Patents/2021/1377.html
        https://www.theregister.com/2021/04/16/facebook_voxer_ip_patent_trial/
        https://www.mondaq.com/uk/patent/1076680/facebook-ireland-limited-v-voxer-ip-llp
        https://jakemp.com/en/news/facebook-succeed-in-invalidating-voxers-live-broadcast-patent-in-the-uk

        • 分类:最新消息
        • 作者:华讯知识产权
        • 来源:
        • 发布时间:2021-11-17 15:08
        • 访问量:
        详情

        Facebook wins the patent infringement lawsuit against Voxer in the UK

        In May, the UK High Court found that social media platforms Facebook and Instagram do not infringe a patent owned by Voxer. Furthermore, Facebook succeeded in invalidating Voxer’s “Live Broadcast” patent.

         

        Voxer is an American app development company, and it is best known for its free Voxer Walkie Talkie app for smartphones, providing a live “push-to-talk” system and a voice messaging system. The patent in issue was EP (UK) 2 393 259 entitled “Telecommunication and Multimedia Management Method and Apparatus”. The invention relates to enabling two-mode conversation. Users can communicate in either a near-synchronous or “live” conversation. The two modes provide a user experience in a standard full-duplex phone call or in a series of back and forth time-delayed transmissions. Therefore, two individual users can send recorded voice messages back and forth to each other and review the messages whenever convenient, or at a rate where they essentially merge into a live, synchronous voice conversation.

         

        In 2020 in the UK, Voxer contended that Facebook infringed the EP259 patent through Facebook and Instagram’s live functionality feature over the iOS operating system. However, Facebook then counterclaimed the invalidity in 2021 as an action for revocation and denying infringement. Facebook challenged the validity on various grounds. Facebook mentioned two reference documents and stated that the claims lack novelty and/or are obvious over the prior art: WO 2006/121550 (Atarius) and US 2006/0003740 A1 (Munje). Both were published before the earlier claimed priority date of the patent. Facebook also stated that the claims are invalid for insufficiency. The patent was based on a lack of novelty and/or obviousness over two pieces of prior art cited by Voxer in its patent application.

         

        At first, presiding judge Birss allowed Voxer’s two unconditional claims to amend the patent, which made the patent novel, not obvious, and sufficient. Finally, however, Birss found the patent obvious over US 2006/0003740 A1 (Munje). As a result, the UK High Court has decided that EP 259 is non-infringed and invalid, and revoked the patent. The case therefore represents a success for Facebook in the UK, although proceedings are ongoing in the US and Germany.

         

        In the US and Germany, decisions have gone the other way for Facebook. In May 2021, the Patent Trial and Appeal Board in the Western District of Texas found four Voxer patents valid. Furthermore, in June, Munich Higher Regional Court found that the ‘Live’ functionality in the Facebook and Instagram iOS apps and the Facebook website infringed the Voxer patent.

         

        Coming from different decisions in three countries, the patent battle between the two companies is still hanging in the balance.

        Reference:

        1. Facebook and Voxer take live broadcast patent dispute to Europe - JUVE Patent (juve-patent.com)
        2. Facebook Ireland Ltd v Voxer IP LLC [2021] EWHC 657 (Pat) (19 March 2021) (bailii.org)
        3. Facebook Ireland Ltd v Voxer IP LLC [2020] EWHC 1806 (Pat) (07 July 2020) (bailii.org)
        4. https://www.bailii.org/ew/cases/EWHC/Patents/2021/1377.html
        5. https://www.theregister.com/2021/04/16/facebook_voxer_ip_patent_trial/
        6. https://www.mondaq.com/uk/patent/1076680/facebook-ireland-limited-v-voxer-ip-llp
        7. https://jakemp.com/en/news/facebook-succeed-in-invalidating-voxers-live-broadcast-patent-in-the-uk
        关键词:

        Ruige

        Ruige Pharmaceutical's New Generation of CDK2/4/6 Small-molecule Inhibitor Receives FDA Approval for Clinical Research

        Established in 2018, Ruige Pharmaceutical?is committed to the fields of tumors, autoimmunity and metabolism, and develops "first-in-class" and "best-in-class" innovative drugs with independent intellectual property rights. Recently, Ruige Pharmaceutical?announced that its new generation of CDK2/4/6 small- molecule inhibitor RGT-419B has been received FDA approval for clinical research. RGT-419B is a new-generation tumor-targeted inhibitor with an optimized kinase activity spectrum. It is expected to improve the safety of currently approved CDK4/6 inhibitors and overcome resistance to these inhibitors. These inhibitors are used in combination with endocrine therapy to treat patients with premenopausal/postmenopausal hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer. In cell model experiments, RGT-419B showed single-drug activity, which has a greater inhibitory effect on the growth of estrogen receptor positive (ER+) tumor cells. In ER+ breast cancer cells resistant to currently approved CDK4/6 inhibitors, RGT-419B showed complete inhibition of cancer cell proliferation. In these experiments, when RGT-419B is used in combination with a selective estrogen receptor degrader or PI3K signaling pathway inhibitor, its inhibitory effect on tumor cells is further enhanced. As a single agent and used in combination with other approved therapies, RGT-419B will initially be developed for the treatment of human epidermal growth factor receptor 2 negative (HER2-), ER+ breast cancer patients who have primary or acquired resistance to CDK4/6 inhibitors. With the widespread adoption of CDK4/6 inhibitors in clinical practice, patients with refractory and relapsed patients are becoming larger and clinically significant unmet medical needs. The clinical development project of RGT-419B will solve this resistance to CDK4/6 and other hormone receptor modulating therapies, and provide new opportunities for improving the survival and quality of life of patients with advanced breast cancer. RGT-419B is the first of many innovative oncology drugs being developed by Ruige Pharmaceutical. Founder and CEO Dr. Qiu Xiayang said: "This milestone marks the successful entry of Ruige Pharmaceutical into the field of tumor treatment. We have found the best choice for multiple CDKs through our self-developed AI-assisted new drug development CARD platform. Successfully promoted innovative drugs to enter the clinical development stage in the United States. At the same time, we are very excited that this opportunity can bring new and differentiated treatment options to many breast cancer patients around the world.
        2021-12-30
        台湾华讯入驻台湾国际半导体大会

        台湾华讯入驻台湾国际半导体大会

        此次大会全称为台湾国际半导体展(SEMICON Taiwan 2021)由国际半导体产业协会(SEMI)主办。
        2021-12-28
        华讯参展2021云上南京软博会

        华讯参展2021云上南京软博会

        华讯一直行走在软件信息的专利顾问服务前沿,紧跟软件信息产业发展的脚步,致力于为企业提供最专业的知识产权服务,为中国软件信息产业的发展出一份力。
        2021-12-27
        原告被告都是国外企业

        原告被告都是国外企业 他们竟纷纷选择到中国提起诉讼?

        这是一个有趣的趋势:由于种种原因,国外企业纷纷选择在中国提起专利诉讼,起诉非中国企业。
        2021-12-24
        上一页
        1
        2
        ...
        145
        这是描述信息

        江苏省南京市江北新区江淼路88号腾飞大厦B座20层2001

        版权所有◎南京华讯知识产权顾问有限公司

        备案号:苏ICP备xxxxxx号-1    网站建设:中企动力 南京

        亚洲AV无码一区二区乱子伦,久久精品中文字幕一区,色费女人18毛片A级毛片视频,欧美+日本+国产+A∨观看